Search

Search Constraints

You searched for: Author/Creator Voit, Thomas

Search Results

1. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Issue 1 (December 2017)

2. PO195 Outcome measures for duchenne muscular dystrophy: implications for trials. (1st December 2017)

3. Rescue of cardiomyopathy through U7snRNA‐mediated exon skipping in Mybpc3‐targeted knock‐in mice. Issue 7 (29th May 2013)

4. RIPK3‐mediated cell death is involved in DUX4‐mediated toxicity in facioscapulohumeral dystrophy. Issue 6 (22nd October 2021)

5. Downregulation of miRNA-29, -23 and -21 in urine of Duchenne muscular dystrophy patients. (22nd March 2018)

6. CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy. Issue 1 (December 2015)

8. Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy. Issue 4 (29th August 2016)

9. Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy. Issue 3 (26th May 2021)

10. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Issue 9979 (2nd May 2015)